Core Viewpoint - The stock of Peijia Medical (02565) surged over 20% to a new high of HKD 62.25 following the announcement of a strategic partnership with UAE-based PDC FZ-LLC for the commercialization of its core product Visepegenatide (PB-119) in the Middle East and Africa [1] Company Summary - Peijia Medical's stock rose by 16.51% to HKD 60.3 with a trading volume of HKD 30.23 million [1] - The strategic partnership with PDC FZ-LLC grants exclusive rights for the development, distribution, marketing, and commercialization of Visepegenatide (PB-119) in the Middle East and Africa [1] - This collaboration represents a significant step in Peijia Medical's global commercialization strategy [1] Product Summary - Visepegenatide (PB-119) is a self-developed GLP-1 receptor agonist administered via weekly subcutaneous injection, aimed at treating type 2 diabetes and weight management [1] - The prevalence of diabetes among adults in the Middle East and North Africa is reported at 16.2%, the highest globally, indicating a substantial market opportunity for Visepegenatide [1] - The partnership is expected to accelerate the availability of this innovative therapy to address unmet medical needs in the region [1]
派格生物医药-B尾盘涨超20%再创新高 近期授出糖尿病药物于中东及非洲独家许可